Condition (MeSH)
Sertoli-Leydig Cell Tumor
ClinicalTrials.gov lists 9 trials for Sertoli-Leydig Cell Tumor or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
6 of the 9 trials are tagged with Sertoli-Leydig Cell Tumor itself; the rest are tagged with a narrower condition beneath it.
When did Sertoli-Leydig Cell Tumor trials start? (7)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 2
- Not applicable
- Observational
Top of scale: 2
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2024 | 1 |
| 2016 | 1 |
| 2012 | 2 |
| 2010 | 2 |
| 2008 | 1 |
| 2005 | 1 |
| 2000 | 1 |
No forecast is made for this condition: it averages 0.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 9 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Sertoli-Leydig Cell Tumor trials in? (4)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 4 |
| Not applicable | 1 |
| Observational | 3 |
How many Sertoli-Leydig Cell Tumor trials are recruiting? (3)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 2 |
| Completed | 6 |
| Unknown status | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Sertoli-Leydig Cell Tumor trials? (4)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Children's Oncology Group | 1 |
| GOG Foundation | 1 |
| Gynecologic Oncology Group | 1 |
| National Cancer Institute (NCI) | 1 |
Which serious adverse events do Sertoli-Leydig Cell Tumor trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Neutrophil Count Decreased | 12 | 1 |
| Hyperglycemia | 4 | 3 |
| Obstruction, Gi - Small Bowel Nos | 3 | 1 |
| Constipation | 2 | 1 |
| Febrile Neutropenia | 2 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Sertoli-Leydig Cell Tumor? (10)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Outcomes in ovarian Sertoli-Leydig cell tumor: A report from the International Pleuropulmonary Blastoma/DICER1 and Ovarian and Testicular Stromal Tumor Registries. | Gynecologic oncology | 2024 | Yes |
| Testicular Sertoli cell tumour and potentially testicular Leydig cell tumour are features of <i>DICER1</i> syndrome. | Journal of medical genetics | 2022 | Yes |
| Thoracic Sertoli-Leydig cell tumor: An alternative type of pleuropulmonary blastoma associated with DICER1 variation. | Pediatric blood & cancer | 2021 | Yes |
| DICER1-related Sertoli-Leydig cell tumor and gynandroblastoma: Clinical and genetic findings from the International Ovarian and Testicular Stromal Tumor Registry. | Gynecologic oncology | 2017 | Yes |
| The prevalence of DICER1 pathogenic variation in population databases. | International journal of cancer | 2017 | Yes |
Showing 5 of 10 publications.
Sub-conditions in MeSH (1)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.
Not computed for conditions with fewer than 10 trials: drugs tested.